Brian M. Fox
Amgen (United States)(US)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Cancer therapeutics and mechanisms, Microtubule and mitosis dynamics, Ubiquitin and proteasome pathways, Click Chemistry and Applications
Most-Cited Works
- → Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development(2014)291 cited
- → Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction(2012)167 cited
- → Synthesis of New Indeno[1,2-c]isoquinolines: Cytotoxic Non-Camptothecin Topoisomerase I Inhibitors(2000)164 cited
- → Synthesis of New Dihydroindeno[1,2-c]isoquinoline and Indenoisoquinolinium Chloride Topoisomerase I Inhibitors Having High in Vivo Anticancer Activity in the Hollow Fiber Animal Model(2001)94 cited
- → Design, Synthesis, and Biological Evaluation of Cytotoxic 11-Alkenylindenoisoquinoline Topoisomerase I Inhibitors and Indenoisoquinoline−Camptothecin Hybrids(2003)92 cited
- → Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction(2014)83 cited
- → A Selective Prostaglandin E2 Receptor Subtype 2 (EP2) Antagonist Increases the Macrophage-Mediated Clearance of Amyloid-Beta Plaques(2015)61 cited
- → Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres(2014)54 cited
- → Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2–p53 Interaction(2014)47 cited
- → Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors(2010)42 cited